Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2024 | $60.00 | Outperform | Wolfe Research |
| 6/4/2024 | $53.00 | Buy | Guggenheim |
| 1/17/2024 | $25.00 → $45.00 | Neutral → Buy | Goldman |
| 9/27/2023 | $27.00 | Buy | Berenberg |
| 1/5/2023 | $33.00 | Sector Outperform | Scotiabank |
| 1/3/2023 | $28.00 → $36.00 | In-line → Outperform | Evercore ISI |
| 3/2/2022 | Outperform | Cowen | |
| 2/7/2022 | $130.00 → $75.00 | Overweight | Barclays |
Wolfe Research initiated coverage of Twist Bioscience with a rating of Outperform and set a new price target of $60.00
Guggenheim initiated coverage of Twist Bioscience with a rating of Buy and set a new price target of $53.00
Goldman upgraded Twist Bioscience from Neutral to Buy and set a new price target of $45.00 from $25.00 previously
144 - Twist Bioscience Corp (0001581280) (Subject)
10-Q - Twist Bioscience Corp (0001581280) (Filer)
8-K - Twist Bioscience Corp (0001581280) (Filer)